DPP4 and prostate carcinoma: Using the SEER-Medicare database, Shah et al. demonstrated that prostate cancer patients on DPP4 inhibitors alone had improved survival compared to those who were not on DPP4 inhibitors, independent of metformin (HR: 0.77; 95% CI: 0.64-0.93; p = 0.0005).